Safety of perinatal exposure to antiretroviral medications: Developmental outcomes in infants

Pediatric Infectious Disease Journal

Volumn 32, Issue 6, 2013, Pages 648-655

  Sirois, Patricia A ^a   Huo, Yanling ^b   Williams, Paige L ^b   Malee, Kathleen ^c   Garvie, Patricia A ^d   Kammerer, Betsy ^e   Rich, Kenneth ^f   Van Dyke, Russell B ^a   Nozyce, Molly L ^g  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Consulting Psychologist ^*  (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antiretroviral; Developmental assessment; HIV; Infant; Neurodevelopment

Indexed keywords

ATAZANAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; TENOFOVIR DISOPROXIL;

ADAPTIVE BEHAVIOR; ARTICLE; BAYLEY SCALES OF INFANT DEVELOPMENT; COGNITION; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DRUG SAFETY; FETUS OUTCOME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LANGUAGE; MAJOR CLINICAL STUDY; MOTOR PERFORMANCE; NERVE CELL DIFFERENTIATION; PATIENT MONITORING; PREGNANCY; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PSYCHOSOCIAL DEVELOPMENT; SUBSTANCE ABUSE;

ANTI-RETROVIRAL AGENTS; CHILD DEVELOPMENT; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; NERVOUS SYSTEM; PERINATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES;

EID: 84879233828     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318284129a     Document Type: Article

References (54)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
2. Heidari S, Mofenson L, Cotton M F, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr. 2011;57:290-296.
3. Whitmore SK, Zhang X, Taylor AW, et al. Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr. 2011;57:218-222.
4. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf. 2007;30:203-213.
5. Funk MJ, Belinson SE, Pimenta JM, et al. Mitochondrial disorders among infants exposed to HIV and antiretroviral therapy. Drug Saf. 2007;30:845-859.
6. Velinov M, Dolzhanskaya N, Mendez H. Mitochondrial T9098C sequence change in the MTATP6 gene and development of severe mitochondrial disease after in utero antiretroviral prophylaxis. Pharmacotherapy. 2009;29:1491.
7. McKeegan K, Rutstein R, Lowenthal E. Postnatal infant HIV prophylaxis: a survey of U.S. practice. AIDS Patient Care STDS. 2011;25:1-4.
8. Ivanovic J, Nicastri E, Anceschi MM, et al.; Pregnancy And Newborn Clinical Outcome Group in HIV Infection (PANCOH). Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res. 2009;7:620-625.
9. Griner R, Williams PL, Read JS, et al.; Pediatric HIV/AIDS Cohort Study. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS. 2011;25:385-394.
10. Calamandrei G, Valanzano A, Puopolo M, et al. Developmental exposure to the antiretroviral drug zidovudine increases brain levels of brain-derived neurotrophic factor in mice. Neurosci Lett. 2002;333:111-114.
11. Fundarò C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299-300.
12. Rajlakshmi C, Bhattacharyya A, Trigunayat A, et al. Neurobehavioral profile of F1 and F2 generation mice following one stage zidovudine exposure through pregnancy and lactation. Annals of Neurosciences. 2008;15:69-74.
13. Venerosi A, Valanzano A, Puopolo M, et al. Neurobehavioral effects of prenatal exposure to AZT: a preliminary investigation with the D1 receptor agonist SKF 38393 in mice. Neurotoxicol Teratol. 2005;27:169-173.
14. Divi RL, Leonard SL, Walker BL, et al. Erythrocebus patas monkey offspring exposed perinatally to NRTIs sustain skeletal muscle mitochondrial compromise at birth and at 1 year of age. Toxicol Sci. 2007;99:203-213.
15. Divi RL, Einem TL, Fletcher SL, et al. Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs). Toxicol Sci. 2010;118:191-201.
16. Gerschenson M, Nguyen V, Ewings EL, et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses. 2004;20:91-100.
17. Poirier MC, Olivero OA, Walker DM, et al. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol. 2004;199:151-161.
18. Rondinini C, Venerosi A, Branchi I, et al. Long-term effects of prenatal 3'-azido-3'-deoxythymidine (AZT) exposure on intermale aggressive behaviour of mice. Psychopharmacology (Berl). 1999;145:317-323.
19. Venerosi A, Cirulli F, Lil'p IG, et al. Prolonged perinatal exposure to AZT affects aggressive behaviour of adult CD-1 mice. Psychopharmacology (Berl). 2000;150:404-411.
20. Venerosi A, Valanzano A, Alleva E, et al. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice. Teratology. 2001;63:26-37.
21. Venerosi A, Cirulli F, Capone F, et al. Prolonged perinatal AZT administration and early maternal separation: effects on social and emotional behaviour of periadolescent mice. Pharmacol Biochem Behav. 2003;74: 671-681.
22. Venerosi A, Calamandrei G, Alleva E. Animal models of anti-HIV drugs exposure during pregnancy: effects on neurobehavioral development. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:747-761.
23. Benhammou V, Tardieu M, Warszawski J, et al. Clinical mitochondrial dysfunction in uninfected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues. Environ Mol Mutagen. 2007;48:173-178.
24. Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother. 2008;61:8-12.
25. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
26. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:380-387.
27. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359:1178-1186.
28. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21:929-938.
29. Brogly SB, DiMauro S, Van Dyke RB, et al. Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIVuninfected children. AIDS Res Hum Retroviruses. 2011;27:777-783.
30. Ciaranello AL, Seage GR 3rd, Freedberg KA, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS. 2008;22:2359-2369.
31. Alimenti A, Forbes JC, Oberlander T F, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics. 2006;118:e1139-e1145.
32. Williams PL, Marino M, Malee K, et al.; PACTG 219C Team. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics. 2010;125:e250-e260.
33. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999;281:151-157.
34. Lindsey JC, Malee KM, Brouwers P, et al.; PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics. 2007;119:e681-e693.
35. Malee KM, Tassiopoulos K, Huo Y, et al.; Pediatric HIV/AIDS Cohort Study Team. Mental health functioning among children and adolescents with perinatal HIV infection and perinatal HIV exposure. AIDS Care. 2011;23:1533-1544.
36. Bradley RH, Corwyn RF. Socioeconomic status and child development. Annu Rev Psychol. 2002;53:371-399.
37. Brooks-Gunn J, Duncan GJ. The effects of poverty on children. Future Child. 1997;7:55-71.
38. Dionne G, Boivin M, Séguin JR, et al. Gestational diabetes hinders language development in offspring. Pediatrics. 2008;122:e1073-e1079.
39. Many A, Fattal A, Leitner Y, et al. Neurodevelopmental and cognitive assessment of children born growth restricted to mothers with and without preeclampsia. Hypertens Pregnancy. 2003;22:25-29.
40. th week. Am J Obstet Gynecol. 2010;203:138.e1-138.e8.
41. Schuler ME, Nair P, Harrington D. Developmental outcome of drug-exposed children through 30 months: a comparison of Bayley and Bayley-II. Psychol Assess. 2003;15:435-438.
42. Bayley N. Bayley Scales of Infant and Toddler Development. Third Edition. San Antonio: Harcourt Assessment Inc.; 2006.
43. Wechsler D. Wechsler Abbreviated Scale of Intelligence. San Antonio: The Psychological Corporation; 1999.
44. Aidala A, Havens J, Mellins CA, et al. Development and validation of the Client Diagnostic Questionnaire (CDQ): A mental health screening tool for use in HIV/AIDS service settings. Psychol Health Med. 2004;9: 362-379.
45. Schulte J, Dominguez K, Sukalac T, et al.; Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics. 2007;119:e900-e906.
46. Townsend C, Schulte J, Thorne C, et al.; Pediatric Spectrum of HIV Disease Consortium, the European Collaborative Study and the National Study of HIV in Pregnancy and Childhood. Antiretroviral therapy and preterm delivery - a pooled analysis of data from the United States and Europe. BJOG. 2010;117: 1399-1410.
47. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204:506-514.
48. Vander-Weele TJ, Mumford SL, Schisterman EF. Conditioning on intermediates in perinatal epidemiology. Epidemiology. 2012;23:1-9.
49. McCarton CM, Wallace I F, Divon M, et al. Cognitive and neurologic development of the premature, small for gestational age infant through age 6: comparison by birth weight and gestational age. Pediatrics. 1996;98(6 Pt 1):1167-1178.
50. Morse SB, Zheng H, Tang Y, et al. Early school-age outcomes of late preterm infants. Pediatrics. 2009;123:e622-e629.
51. Letendre S, Marquie-Beck J, Capparelli E, et al.; CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
52. Tozzi V, Balestra P, Salvatori M F, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009;52:56-63.
53. Mandelbrot L, Mazy F, Floch-Tudal C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol Reprod Biol. 2011;157:18-21.
54. Tassiopoulos K, Read JS, Brogly S, et al. Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis. AIDS Behav. 2010;14:1269-1278.